SFEBES2023 Poster Presentations Thyroid (63 abstracts)
1Department of Endocrinology & Diabetes, Medical School, European University Cyprus, Nicosia, Cyprus. 2CEDM Centre of Endocrinology, Diabetes & Metabolism, Limassol, Cyprus. 3School of Health Sciences, University of Stirling, Stirling, United Kingdom. 4Alithias Endocrinology Cente, Nicosia, Cyprus. 5Diabetes, Endocrinology & Obesity Medicine, Salford Royal NHS Foundation Trust, Salford, Greater Manchester, United Kingdom. 6Division of Diabetes, Endocrinology & Gastroenterology, Faculty of Biology, Medicine & Health, The University of Manchester, Manchester, United Kingdom
Background: Overshoot of weight regain following the treatment of hyperthyroidism is well described. Notwithstanding, there is a large interindividual variability in the observed weight changes. This study aims to identify parameters predicting excessive weight gain in hyperthyroidism patients.
Methods: In a retrospective study of a prospectively completed database, we recruited consecutive patients with overt hyperthyroidism and compared those with excessive weight gain (≥10%, Group A) to those with less gain (<10%, Group B) based on initial anthropometrics, demographics, and disease-related characteristics, using appropriate statistical tests.
Results: We recruited 91 patients (70.3% females, median age 50 years) treated for hyperthyroidism with a median follow-up of 2 years. Excessive weight gain (GpA) was observed in 50% of patients. GpA had significantly higher ft4 levels and disease-related weight loss at presentation.
Parameters | Group A: ≥ 10% weight gain n (%) or median | Group B: < 10% weight gain n (%) or median | P-value |
All | 45 (49.5%) | 46 (50.5%) | |
Sex | 0.104 | ||
Male | 19 (61.29%) | 12 (38.71%) | |
Female | 26 (43.44%) | 34 (56.67%) | |
Ethnicity | 0.449 | ||
Cypriots | 38 (51.35%) | 36 (48.65%) | |
Non-Cypriots | 7 (41.18%) | 10 (58.82%) | |
Smoking status | 0.105 | ||
Smokers | 17 (56.67%) | 13(43.33%) | |
Ex-smokers | 1 (14.29%) | 6 (85.71%) | |
Never smokers | 22 (46.81%) | 25 (53.19%) | |
BMI-0 (kg/m2) | 24.31 | 25.16 | 0.592 |
TSH-0 (mIU/l) | .010 | 0.14 | 0.156 |
ft4 (t=0) (ng/dL) | 52.94 | 36.92 | <0.001 |
Disease-related weight loss (t=0) (kg) | 8.17 | 2.68 | <0.001 |
TRAb levels (t=0) (IU/l) | 10.04 | 10.54 | 0.390 |
Peak TSH levels (mIU/l) | 6.137 | 5.39 | 0.475 |
Treatment | 0.535 | ||
ATDs | 40 (51.28%) | 38 (48.72%) | |
ATDs & surgery | 5 (45.45%) | 6.1 (54.55%) | |
Diagnosis | 0.311 | ||
Graves disease | 41 (52.56%) | 37 (47.44%) | |
Toxic Nodular Goiter | 3 (30%) | 7 (70%) |
Conclusion: The severity of thyrotoxicosis and the disease-related weight loss were predictive of excessive weight gain post-treatment. This information alongside the presentation BMI may allow risk stratification for excessive weight gain, hereby permitting early intervention strategies.